You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

~ Buy the XPOVIO (selinexor) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR XPOVIO

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for XPOVIO

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01607905 ↗	Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer	Completed	Karyopharm Therapeutics Inc	Phase 1	2012-06-18	Phase 1 study to evaluate the safety and tolerability of selinexor and determine the Recommended Phase 2 Dose (RP2D) of selinexor for advanced or metastatic solid tumor malignancies.
NCT01607905 ↗	Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer	Completed	Karyopharm Therapeutics, Inc	Phase 1	2012-06-18	Phase 1 study to evaluate the safety and tolerability of selinexor and determine the Recommended Phase 2 Dose (RP2D) of selinexor for advanced or metastatic solid tumor malignancies.
NCT02025985 ↗	Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies	Completed	Karyopharm Therapeutics Inc	Phase 2	2014-04-09	The primary trial objective is to determine the efficacy of KPT-330 (selinexor) in participants with advanced or metastatic gynaecological cancers by disease control rate (complete response (CR) or partial response (PR) or stable disease (SD) for at least 12 weeks, assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
NCT02025985 ↗	Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies	Completed	Karyopharm Therapeutics, Inc	Phase 2	2014-04-09	The primary trial objective is to determine the efficacy of KPT-330 (selinexor) in participants with advanced or metastatic gynaecological cancers by disease control rate (complete response (CR) or partial response (PR) or stable disease (SD) for at least 12 weeks, assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
NCT02178436 ↗	Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer	Recruiting	National Cancer Institute (NCI)	Phase 1/Phase 2	2014-10-31	This partially randomized phase Ib/II trial studies the side effects and best dose of selinexor when given together with gemcitabine and nab-paclitaxel, and to see how well they work in treating patients with pancreatic cancer that has spread to other parts of the body (metastatic). Drugs used in chemotherapy, such as selinexor, gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for XPOVIO

Condition Name

Chart
Table

Condition Name for XPOVIO
Intervention	Trials
Multiple Myeloma	3
Ovarian Carcinoma	2
Refractory Plasma Cell Myeloma	2
Coronavirus Infection	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for XPOVIO
Intervention	Trials
Neoplasms, Plasma Cell	8
Multiple Myeloma	8
Carcinoma	4
Neoplasms	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for XPOVIO

Trials by Country

Map
Table

Trials by Country for XPOVIO
Location	Trials
United States	76
Greece	4
Denmark	3
China	3
Israel	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for XPOVIO
Location	Trials
New York	7
Florida	6
California	5
Texas	5
Michigan	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for XPOVIO

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for XPOVIO
Clinical Trial Phase	Trials
Phase 2	12
Phase 1/Phase 2	6
Phase 1	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for XPOVIO
Clinical Trial Phase	Trials
Recruiting	12
Not yet recruiting	7
Completed	3
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for XPOVIO

Sponsor Name

Chart
Table

Sponsor Name for XPOVIO
Sponsor	Trials
Karyopharm Therapeutics Inc	13
National Cancer Institute (NCI)	10
Karyopharm Therapeutics, Inc	3
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for XPOVIO
Sponsor	Trials
Industry	19
Other	14
NIH	10
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.